Reimbursement models to practicing physicians continue to evolve. Many oncologists have been skeptical about MACRA (which was enacted into law) and how it might affect their ability to deliver cost-effective care, without compromising patients’ access to life-saving therapies. in this OBR interview, which was conducted during the 2018 annual American Society of Hematology (ASH) meeting, I review findings from market research studies that we conducted when I was at Cardinal Health. This research highlighted the skepticism about MACRA, and should serve as a warning sign to regulators to adjust these models so that patients and physicians are served best. At the time of this interview, I was a VP and CMO at Cardinal Health Specialty Solutions.
Menu